Patent intelligence · US
US 11648247
Compositions and methods for the treatment of presbyopia
Compositions and methods for the treatment of presbyopia
Patent details — US 11648247
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 16, 2023
- Expiration
- May 11, 2043
- Applicant
- Lenz Therapeutics, Inc.
- Claims
- 5
- CPC classes
- A61K, A61K31/439, A61K31/498, A61K47/02
Quick answer
US 11648247 (Compositions and methods for the treatment of presbyopia) is held by Lenz Therapeutics, Inc.. Status: granted. Granted May 16, 2023. Expires May 11, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Lenz Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/439, A61K31/498, A61K47/02, A61K47/10, A61K47/12
More from Lenz Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12414942
Compositions, methods, and systems for treating presbyopia
granted -
US 12180206
Aceclidine derivatives, compositions thereof and methods of use thereof
granted -
US 12128036
Compositions and methods for storage stable ophthalmic drugs
granted -
US 11344538
Methods for the treatment of myopia
granted -
US 11273150
Compositions and methods for the treatment of presbyopia
granted -
US 11214569
Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereof
granted -
US 11179328
Compositions and methods for the treatment of presbyopia
granted
Frequently asked questions
What is US patent 11648247?
US 11648247 (Compositions and methods for the treatment of presbyopia) is held by Lenz Therapeutics, Inc.. Status: granted. Granted May 16, 2023. Expires May 11, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11648247?
Lenz Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 11648247 expire?
Our index shows an expiration date of May 11, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.